Previous 10 | Next 10 |
BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will present clinical electroencepha...
Radnor, Pennsylvania--(Newsfile Corp. - July 9, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") investors that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common ...
Athira Pharma (ATHA) has started enrolling patients into an open label extension ((OLEX)) study for its ongoing Phase 2/3 LIFT-AD and Phase 2 ACT-AD studies of ATH-1017 for the treatment of mild-to-moderate Alzheimer’s disease.The trials are evaluating ATH-1017, a small molecule t...
BOTHELL, Wash., July 06, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it is enrolling patients into an open l...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - July 2, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm,...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 30, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm...
Athira shares plunged over 39% on June 18 after founder/CEO Leen Kawas was placed on temporary leave due to an ongoing review into her doctoral research at Washington State University. The review is examining potential misconduct stemming from allegations of altered images in her doct...
CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future. For further details see: Athira Pharma: ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 28, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is i...
Palm Beach, FL – June 24, 2021 – According to the Centers for Disease Control and Prevention, Alzheimer’s is among the top 10 leading causes of deaths in the United States. The death rate for the disease has increased significantly in the U.S. over the past few years. M...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...